What are biotech stocks?

Biotech stocks are companies that use biological science to develop products, most commonly drugs and medical treatments. They range from small companies with a single drug in clinical trials to large commercial businesses with multiple approved products on the market.

What is longevity investing?

Longevity investing involves investing in companies developing treatments, therapies, and technologies to extend healthy human life. The category increasingly overlaps with mainstream biotech, as drugs originally developed for diabetes, obesity, and cancer begin showing evidence of broader life-extension effects.

Why did biotech stocks perform well in 2025?

After three years of underperformance that left the sector trading at historically cheap valuations, biotech stocks rebounded in 2025 on the back of near-record FDA drug approvals, a surge in acquisition activity from large pharma companies racing to replace revenue before key patents expire, and growing investor interest in longevity science.

Biotech Stocks & Longevity Investing: Trends to Track

The data behind biotech's comeback, and why longevity is becoming a mainstream investment theme.

By Jack Caporal – Updated Mar 17, 2026 at 2:50 PM EST

Key Points

Biotech stocks saw a major rebound in 2025, with key indexes significantly outperforming the S&P 500.
Private investment in longevity science doubled in 2024, highlighting growing interest in aging-related therapies.
Big pharma's increased acquisition of biotech firms in 2025 suggests a strategic focus on replenishing drug pipelines.

Loading paragraph...

For individual investors tracking the intersection of biotech stocks and longevity, the data points in the same direction across many angles: drug performance, new-drug pipelines, private capital, government support, and demographics. The question is no longer whether longevity is a viable investment theme but how much of the opportunity is already priced in and how much is still ahead.

FAQs

Sources

The Association of Investment Companies (2025). “M&A activity drives momentum in biotech and healthcare.”
BioSpace (2026). “The Five Biggest Biopharma Takeovers of 2025.”
BioXconomy (2025). “BioXconomy’s top 10 M&A deals of 2025.”
Businesswire (2025). “Loyal Receives FDA Acceptance of Reasonable Expectation of Effectiveness for Senior Dog Lifespan Extension.”
Centers for Medicare and Medicaid Services (2025). “NHE Fact Sheet.”
Drug Discovery and Development (2025). “Top 25 drugs by sales: 2025 H1”
Evaluate (2025). “Obesity and GLP-1 Dealmaking: Strategic Trends and Market Signals.”
Evaluate (2025). “Portfolio Tactics to Scale the $300bn Patent Cliff.”
FDA (2026). “New Drug Therapy Approvals 2025.”
FierceBiotech (2025). “2025 M&A up in value and deal count after year of 'conservatism and recovery': Leerink Partners.”
JPMorgan (2026). “Biopharma and medtech activity in Q4 2025.”
Longevity.Technology (2025). “Longevity investment more than doubled to $8.5bn in 2024.”
Longevity.Technology (2026). “FDA rewrites drug approval rules and longevity stands to gain.”
Nature Biotechnology (2025). “Are GLP-1s the first longevity drugs?”
Swiss Re (2025). “GLP-1 drugs may reduce mortality by up to 6.4% in the US by 2045.”
Vision Lifesciences (2026). “Pharma M&A Tracker 2026: Every Major Deal, Decoded.”

About the Author

Jack Caporal is the Research Director for The Motley Fool and Motley Fool Money. Jack leads efforts to identify and analyze trends shaping investing and personal financial decisions across the United States. His research has appeared in thousands of media outlets including Harvard Business Review, The New York Times, Bloomberg, and CNBC, and has been cited in congressional testimony. He previously covered business and economic trends as a reporter and policy analyst in Washington, D.C. He serves as Chair of the Trade Policy Committee at the World Trade Center in Denver, Colorado. He holds a B.A. degree in International Relations with a concentration in International Economics from Michigan State University.

TMFJackCap

Jack Caporal has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.

Longevity investment: Where science and capital are going

Longevity is an investment category forming around the science of aging, and private capital, research, and the FDA are moving quickly.

Private investment in longevity science more than doubled in a single year. Global investment in longevity science reached $8.49 billion across 325 deals in 2024, up from $3.82 billion in 2023.

GLP-1 drugs are expanding from weight loss into longevity territory. GLP-1s are a class of drugs that includes semaglutide, sold as Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro. Originally approved for diabetes and obesity, they have since received FDA approval for cardiovascular risk reduction, obstructive sleep apnea, fatty liver disease, and oral obesity treatment. A Swiss Re model estimates that GLP-1 drugs could reduce all-cause U.S. mortality by 6.4% by 2045, making it the first drug class with implications at that scale. The GLP-1 market alone is projected to grow from $55 billion today to $150 billion by 2030.

The FDA formally recognized lifespan extension as a valid clinical goal for the first time. In February 2025, Loyal's LOY-002, a drug for aging dogs, became the first treatment to clear that regulatory bar, marking a milestone for the longevity field's credibility with regulators.

The drugs making some of the most money in biotech right now, like GLP-1s, cancer immunotherapies, and gene medicines, are the same ones showing early signs of potentially extending healthy life. Longevity investing used to mean putting capital behind unproven science. Increasingly, it means owning companies that are already generating revenue, like Novo Nordisk (NVO -0.44%), whose GLP-1 drug Wegovy is already one of the best-selling drugs in the world, according to industry publication Drug Discovery and Development.

What investors tracking biotech and longevity should watch

Biotech stocks enter 2026 with real momentum. The industry is still recovering from a brutal three-year run leading into 2025, big pharma is paying a significant premium to acquire pipeline companies, which are companies with drugs under development, and the FDA is approving new drugs at near-record rates. The sector is grappling with patent expirations as longevity science is gaining traction.

Demographics create a demand floor that isn’t a forecast – the population data is set and is difficult to ignore. Adults 65 and older represent 17% of the U.S. population but make up 37% of all healthcare spending. Individuals aged both 60+ and 80+ will make up a growing share of the global population in the coming decades. That means each passing year brings a larger, older cohort of patients who need treatment for chronic conditions that affect 95% of adults over 60 as well as greater demand for longevity drugs.

Biotech stocks staged a 2025 comeback

After three years of flat or negative returns, biotech stocks broke out in 2025. The biotech trends discussed above and throughout suggest that reversal could be more structural, meaning driven by lasting forces like an aging population and a mounting patent cliff, rather than cyclical, meaning just a temporary bounce.

Biotech indexes outpaced the S&P 500 by a wide margin in 2025. The SDPR S&P Biotech ETX returned 35.9%, the iShares Biotech ETF returned 28.0%, and the Nasdaq Biotech Index (NASDAQ:NBI) gained 31.5%, compared to the S&P 500's 17.9%.

Merger and acquisition (M&A) activity more than doubled 2024 levels. Biopharma M&A deal value through October 2025 hit $65 billion to $70 billion, exceeding full-year totals for 2024, 2022, and 2021. At least seven deals topped $8 billion.

Big pharma faces a patent cliff. More than $300 billion in branded drug revenue faces patent expiration between 2025 and 2030. When a patent expires, cheaper generic versions can enter the market. When that happens, the original drug's sales can collapse quickly, so large pharma companies try to replace that revenue before it disappears. Biotech companies develop more than 70% of newly approved drugs, up from around 50% a decade ago, which makes acquiring a biotech one of the fastest ways to fill that gap.

Which parts of biotech had the best 2025 for investors?

Broad biotech funds only tell part of the story. Beyond the headline returns, different parts of the sector performed very differently in 2025. The differences show where individual investors might see the most compelling long-term cases.

The following returns reflect year-to-date performance in 2025 for thematic ETFs, used as subindustry proxies. Ten-year compound annual growth rates (CAGR), which is the average annual return over a 10-year period, reflect each fund’s full available history.

Clinical-stage biotech was the biggest winner in 2025. The Virtus LifeSci Biotech Clinical Trials ETF (NYSE:BBC) returned 63.7%, nearly double the broad XBI, as smaller biotech companies with drugs still in trials got a major boost from stronger FDA approval rates and aggressive acquisition activity from big pharma. The ALPS Medical Breakthroughs ETF (NYSE:SBIO), which holds similar companies, gained 55.1%.

Oncology and genomics also outperformed. The Tema Oncology ETF (CANC -0.64%) gained 42.9% in 2025. The ARK Genomic Revolution ETF (CBOE:ARKG), focused on gene editing and genomic medicine, returned 23.0% after a steep 28.2% decline in 2024. The Global X Genomics and Biotechnology ETF (GNOM +0.68%) gained 18.7%.

Over a decade, the gap between commercial-stage and clinical-stage biotech is stark. Clinical-stage companies are still testing their drugs in human trials and have no products on the market yet. The Virtus LifeSci Biotech Products ETF (NYSE:BBP), which holds commercial-stage companies – those with at least one FDA-approved drug on the market – returned 10.85% annualized over 11 years. XBI, the broad equal-weighted biotech index, returned 6.46% annually over the same period. Genomics-focused ARKG returned just 3.60% annualized despite some explosive individual years, a reminder that early-stage science can be a bumpy ride even when the long-term thesis is compelling.

Biotech Stocks and Longevity Investing: Trends to Track